This video segment reviews the clinical evidence supporting lorlatinib as a first-line treatment for ALK-positive metastatic NSCLC, emphasizing key efficacy outcomes from the phase 3 CROWN trial.
Video content above is prompted by the following:
Stay up to date on recent advances in the multidisciplinary approach to cancer.